Depression

>

Latest News

Depression Increases Risk For and Accrual of Long-Term Health Disorders / image credit University of Edinburgh
Depression Increases Risk For and Accrual of Long-Term Health Disorders

February 21st 2025

Comorbid conditions accrued at a rate 30% faster among adults with depression than in those without the disorder over a 7-year follow-up period.

Vistagen Wins US Patent for Investigational NMDA Receptor Antagonist to Treat Neuropathic Pain / image credit ©fotogurmespb/stock.adobe.com
Vistagen Wins US Patent for Investigational NMDA Receptor Antagonist to Treat Neuropathic Pain

February 10th 2025

New Study Links Major Depressive Disorder to Specific Changes in Eating Preferences / Image credit: ©beats_/AdobeStock
New Study Links Major Depressive Disorder to Specific Changes in Eating Preferences

February 6th 2025

Inhaled Psychedelic GH001 Significantly and Rapidly Reduces Symptoms in Treatment Resistant Depression in Phase 2b Clinical Trial
Inhaled Psychedelic GH001 Significantly and Rapidly Reduces Symptoms in Treatment Resistant Depression in Phase 2b Clinical Trial

February 4th 2025

FDA Approves First Monotherapy Standalone MDD Treatment: Daily Dose / image credit: ©New Africa/AdobeStock
FDA Approves First Monotherapy Standalone MDD Treatment: Daily Dose

January 31st 2025

More News


Site Logo

Effective Pharmacological Treatment Options for Anxiety Disorders

March 1st 2008

Cumulative research with animal, normative, and clinical populations over several decades shows that the mechanisms underlying anxiety disorders differ from those of the normal emotion of anxiety. In persons with anxiety disorders, fear and tension are disproportionate to the actual threat and may be present when no real threat exists, thereby generating an expectation of danger and distorted perceptions related to danger and various types of threats. The most common anxiety disorders are social anxiety disorder (SAD), generalized anxiety disorder (GAD), and posttraumatic stress disorder (PTSD). Persons with SAD can experience a wide range of social fears as well as severe functional consequences, whereas persons with GAD tend to experience emotional, interpersonal, and somatic symptoms of high levels of chronic anxiety. Persons with PTSD have vivid memories of and thoughts about a terrifying event or ordeal that lead to the development of anxiety, depression, and functional impairment. Effective treatment options-pharmacotherapy; psychotherapy, particularly cognitive-behavioral therapy; or a combination-can be discussed openly with the patient to make a collaborative, informed decision. A variety of medications can be used to successfully manage anxiety disorders, of which SSRIs and serotonin-norepinephrine reuptake inhibitors are the most effective. When properly used, medications can enhance a patient's own efforts to master anxiety; overcome fearful avoidance; and address troubling behaviors, patterns, or memories. (Drug Benefit Trends. 2008;20:101-113)

© 2025 MJH Life Sciences

All rights reserved.